DA
INSY

Denali Advisors’s Insys Therapeutics, Inc. INSY Stock Holding History

Denali Advisors’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-2,700
Closed -$56K – 299
2014
Q1 		$56K Buy
+2,700
New +$53.5K 0.02% 134

Other funds holding INSY

JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ECP
Empyrean Capital Partners Los Angeles, California $3.07B AUM 34.24% 1-Year Est. Return
BTP
Bloom Tree Partners New York $215M AUM 17.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Denali Advisors's INSY Position: Q2 2014 in Review

Denali Advisors sold out of Insys Therapeutics, Inc. (INSY) in Q2 2014, closing a stake of 2,700 shares — an estimated $56K sold.

Denali Advisors first reported a position in INSY in Q1 2014 and held it in 1 quarter. The position peaked at $56K in Q1 2014. 99 funds tracked by Wall St. Rank hold INSY as of Q2 2014.

  • Denali Advisors reported no remaining Insys Therapeutics, Inc. position as of Q2 2014 after selling out during the quarter.
  • Denali Advisors sold 2,700 Insys Therapeutics, Inc. shares in Q2 2014, an estimated $56K.
  • Denali Advisors first reported a position in Insys Therapeutics, Inc. in Q1 2014 and held it in 1 quarter.
  • Denali Advisors's Insys Therapeutics, Inc. position peaked at $56K in Q1 2014.
  • 99 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q2 2014.

Based on Denali Advisors's 13F filing for Q2 2014, filed 16 Jul 2014.